Gara Jalqabaatti › Degenereshinii Makulaarii
Qorannoo klinikaalii Degenereshinii Makulaarii Ameerikaa Keessatti hirmaatuu
Qorannoo 55 Degenereshinii Makulaarii f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- Dallas, TXQorannoo 13
- Erie, PAQorannoo 10
- The Woodlands, TXQorannoo 9
- Reno, NVQorannoo 8
- Hagerstown, MDQorannoo 8
- Sacramento, CAQorannoo 8
- Fort Worth, TXQorannoo 7
- Cleveland, OHQorannoo 7
- Salt Lake City, UTQorannoo 7
- Houston, TXQorannoo 7
- Carmel, INQorannoo 7
- Austin, TXQorannoo 7
- Phoenix, AZQorannoo 7
- Boston, MAQorannoo 7
- Santa Monica, CAQorannoo 7
- Naperville, ILQorannoo 6
- Portland, ORQorannoo 6
- Cincinnati, OHQorannoo 6
- Washington, DCQorannoo 6
- Mountain View, CAQorannoo 6
- Philadelphia, PAQorannoo 6
- Nashville, TNQorannoo 6
- Columbia, SCQorannoo 6
- McAllen, TXQorannoo 6
- Raleigh, NCQorannoo 6
- Fort Lauderdale, FLQorannoo 5
- Syracuse, NYQorannoo 5
- Lynchburg, VAQorannoo 5
- Orlando, FLQorannoo 5
- Spokane, WAQorannoo 5
- Tampa, FLQorannoo 5
- Durham, NCQorannoo 5
- San Francisco, CAQorannoo 5
- San Antonio, TXQorannoo 5
- Eugene, ORQorannoo 5
- Pensacola, FLQorannoo 5
- Tyler, TXQorannoo 4
- Memphis, TNQorannoo 4
- Mount Pleasant, SCQorannoo 4
- St. Petersburg, FLQorannoo 4
Naannoon
- ArizonaQorannoo 11
- CaliforniaQorannoo 20
- ColoradoQorannoo 7
- ConnecticutQorannoo 6
- FloridaQorannoo 14
- GeorgiaQorannoo 6
- IllinoisQorannoo 13
- IndianaQorannoo 7
- MarylandQorannoo 11
- MassachusettsQorannoo 14
- MichiganQorannoo 9
- MinnesotaQorannoo 5
- MississippiQorannoo 5
- MissouriQorannoo 5
- NevadaQorannoo 8
- New JerseyQorannoo 7
- New YorkQorannoo 10
- North CarolinaQorannoo 11
- OhioQorannoo 11
- OklahomaQorannoo 3
- OregonQorannoo 9
- PennsylvaniaQorannoo 17
- South CarolinaQorannoo 8
- TennesseeQorannoo 7
- TexasQorannoo 24
- UtahQorannoo 9
- VirginiaQorannoo 7
- WashingtonQorannoo 8
- WisconsinQorannoo 6
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 55 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT06659549A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07440225National Eye Institute Biorepository for Retinal Diseases
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 2 hanga 120 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT01496625A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 60 fi ol · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT06635148A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 55 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT07029945Cell Collection to Study Eye Diseases
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
1 Day – 120 Years · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT01432847A Study in Adults With Geographic Atrophy
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 60 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07606365A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 50 hanga 85 · Saalaa hunda · Haaromfame 18-Ful-2026 · NCT06541704A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07811726The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT06319872A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 6 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07734064Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 55 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06659445A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 55 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07144137Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 50 hanga 80 · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT07798323A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 03-Ful-2026 · NCT03178149A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT06346600Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Ful-2026 · NCT06965426Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
Namoota walitti qabaa jira
Umuriin 60 fi ol · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT06662162SGLT2 Inhibitors in Geographic Atrophy
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 26-Hag-2026 · NCT07174687A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 6 fi ol · Saalaa hunda · Haaromfame 25-Hag-2026 · NCT074255744D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 21-Hag-2026 · NCT05197270Phase 1 Study of C.001 in Retinal Degeneration
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT07594236AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 50 hanga 89 · Saalaa hunda · Haaromfame 10-Hag-2026 · NCT06619405A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 06-Hag-2026 · NCT07496567Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 50 fi ol · Saalaa hunda · Haaromfame 05-Hag-2026 · NCT07230834Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.